|
MEF2D expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.03089999869965E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.23969999990636E-07 |
| Normal-vs-Stage2 |
2.619400E-04 |
| Normal-vs-Stage3 |
3.90219999646391E-08 |
| Normal-vs-Stage4 |
4.958100E-04 |
| Stage1-vs-Stage2 |
9.734400E-01 |
| Stage1-vs-Stage3 |
1.409960E-01 |
| Stage1-vs-Stage4 |
8.554200E-01 |
| Stage2-vs-Stage3 |
3.280800E-01 |
| Stage2-vs-Stage4 |
8.691600E-01 |
| Stage3-vs-Stage4 |
2.397600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.19680000143907E-08 |
| Normal-vs-AfricanAmerican |
1.082770E-01 |
| Normal-vs-Asian |
1.647990E-04 |
| Caucasian-vs-AfricanAmerican |
6.052100E-02 |
| Caucasian-vs-Asian |
9.209600E-01 |
| AfricanAmerican-vs-Asian |
1.066170E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.61600000048168E-07 |
| Normal-vs-Female |
6.40839999954679E-08 |
| Male-vs-Female |
5.401600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62240000001201E-06 |
| Normal-vs-Age(41-60Yrs) |
2.05480000015079E-07 |
| Normal-vs-Age(61-80Yrs) |
2.04709999951369E-07 |
| Normal-vs-Age(81-100Yrs) |
1.646250E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.060600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.890370E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.517400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.966000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.916800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.785000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.73104999999785E-05 |
| Classical-VS-Follicular |
5.583700E-02 |
| Classical-VS-Other |
9.616100E-02 |
| Classical-VS-Normal |
1.87350000002695E-06 |
| Tall-VS-Follicular |
3.138100E-02 |
| Tall-VS-Other |
9.314200E-01 |
| Tall-VS-Normal |
1.11450004780522E-09 |
| Follicular-VS-Other |
3.578200E-01 |
| Follicular-VS-Normal |
1.16429999996726E-06 |
| Other-VS-Normal |
3.224900E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.00110000014853E-07 |
| Normal-vs-N1 |
2.55319999997727E-06 |
| N0-vs-N1 |
6.875200E-01 |
|
|
